AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2217
-0.0052 (-2.29%)
Sep 11, 2026, 4:00 PM EDT - Market closed
AIM ImmunoTech Employees
As of December 31, 2025, AIM ImmunoTech had 21 total employees, including 19 full-time and 2 part-time employees. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
$4,524
Profits / Employee
-$679,524
Market Cap
6.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -2 | -8.70% | 19 | 2 |
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| Evogene | 38 |
| Bolt Biotherapeutics | 23 |
| Cardio Diagnostics Holdings | 17 |
| Purple Biotech | 10 |
| Ernexa Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| Enveric Biosciences | 6 |
AIM News
- 4 days ago - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - GlobeNewsWire
- 11 days ago - AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - GlobeNewsWire
- 13 days ago - AIM ImmunoTech granted patent for Ampligen - TheFly
- 13 days ago - AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - GlobeNewsWire
- 17 days ago - AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Quarterly report: Q2 2026 - Filings
- 5 weeks ago - AIM ImmunoTech Earnings release: Q2 2026 - Filings